Printer Friendly Version

Section: Surgery
Number: S-179
Topic: Myolysis of Uterine Fibroids
Effective Date: January 1, 2007
Issued Date: February 12, 2007
Date Last Reviewed: 01/2007

General Policy Guidelines

Indications and Limitations of Coverage

Laparoscopic (58578) and percutaneous (58999) techniques for myolysis (e.g. laser and bipolar needles, cryomyolysis, laparoscopic radiofrequency ablation [HALT procedure]) in the treatment of uterine fibroids (218.0-218.9) are considered experimental/investigational.  The published data regarding techniques of myolysis are inadequate to permit scientific conclusions due to the lack of randomized trials.  Surgical myolysis, whether performed via laparoscope or percutaneously, is not covered and not eligible for payment.  A participating, preferred, or network provider can bill the member for such procedures.

Description

Uterine fibroids are the most common type of abnormal growth in the uterus and one of the most common conditions affecting women in the reproductive years.  Symptoms include menorrhagia (abnormally heavy bleeding), pelvic pressure, and pain.  Hysterectomy and various myomectomy procedures are considered the gold standard treatment.  However, there has been longstanding interest in developing minimally invasive alternatives that include endometrial ablation (for submucosal fibroids), uterine artery embolization, and various techniques to induce myolysis of fibroids.  A variety of energy sources have been used for myolysis, including Nd:YAG lasers, bipolar electrodes, cryotherapy, and radiofrequency ablation.  Typically, the patients are pretreated with a 2 to 6 month course of depot GnRH agonists to shrink fibroids prior to the procedure.  In general, the procedures involve the insertion of probes multiple times into the fibroid.  When activated, the various energy sources induce devascularization and ultimately ablation of the target tissue.

Myolysis is accomplished using the following techniques:

  • Laser and bipolar needles - These procedures involve the insertion of an Nd: YAG laser or bipolar needle electrodes into uterine fibroids in order to cause coagulation and shrinkage.
  • Cryomyolysis - This technique involves the insertion of a cryoprobe into the center of a uterine fibroid to cause freezing of tissue and resultant reduction in the size of the fibroid.
  • Radiofrequency ablation myolysis of uterine fibroids (e.g., the HALT [hysterectomy alternative] procedure) involves MRI-guided Nd: YAG laser myolysis.

Myolysis is typically performed as a laparoscopic procedure, but more recently, percutaneous approaches using magnetic resonance imaging (MRI) guidance (77022) have been employed.  The MRI can provide both the guidance for insertion of the probe and real-time thermal imaging maps of the treated area.  It can also be used to carry out in vivo monitoring of thermal changes in the tissues.

MRI guidance performed in conjunction with percutaneous myolysis of uterine fibroids is considered experimental/investigational.  A participating, preferred, or network provider can bill the member for the denied service.

NOTE: 
           
 For additional guidelines on the treatment of uterine fibroids, see Medical Policy Bulletins S-77
             (Endometrial Ablation) and S-114 (Uterine Artery Embolization for Uterine Fibroids).
      

 


NOTE:
This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.

Procedure Codes

585785899977022   

Traditional Guidelines

Refer to General Policy Guidelines

FEP Guidelines

This medical policy may not apply to FEP.  Medical policy is not an authorization, certification, explanation of benefits or a contract.  Benefits are determined by the Federal Employee Program.

PPO Guidelines

Refer to General Policy Guidelines

Managed Care POS Guidelines

Refer to General Policy Guidelines

Publications

References

Laparoscopic and Percutaneous Techniques for the Myolysis of Uterine Fibroids, Medical Policy Reference manual, Policy 4.01.19, 07/15/04

View Previous Versions

[Version 002 of S-179]
[Version 001 of S-179]

Table Attachment

Text Attachment

Procedure Code Attachment


Glossary





This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances may warrant individual consideration, based on review of applicable medical records.

Medical policies are designed to supplement the terms of a member's contract. The member's contract defines the benefits available; therefore, medical policies should not be construed as overriding specific contract language. In the event of conflict, the contract shall govern.

Medical policies do not constitute medical advice, nor the practice of medicine. Rather, such policies are intended only to establish general guidelines for coverage and reimbursement under Mountain State Blue Cross Blue Shield plans. Application of a medical policy to determine coverage in an individual instance is not intended and shall not be construed to supercede the professional judgment of a treating provider. In all situations, the treating provider must use his/her professional judgment to provide care he/she believes to be in the best interest of the patient, and the provider and patient remain responsible for all treatment decisions.

Mountain State Blue Cross Blue Shield (MSBCBS) retains the right to review and update its medical policy guidelines at its sole discretion. These guidelines are the proprietary information of MSBCBS. Any sale, copying or dissemination of the medical policies is prohibited; however, limited copying of medical policies is permitted for individual use.



back to top